title: Pretreatment antimicrobial susceptibility testing is not cost saving in the standard eradication of Helicobacter pylori.
authors.forename: Asghar
authors.initials: A
authors.lastname: Qasim
authors.forename: Shaji
authors.initials: S
authors.lastname: Sebastian
authors.forename: Martin
authors.initials: M
authors.lastname: Buckley
authors.forename: Humphrey
authors.initials: H
authors.lastname: O'Connor
authors.forename: Colm
authors.initials: C
authors.lastname: O'Morain
mesh_terms: D000658:Amoxicillin / Q000191:economics / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000191:economics / Q000627:therapeutic use; D017291:Clarithromycin / Q000191:economics / Q000627:therapeutic use; D017046:Cost Savings; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D004415:Dyspepsia / Q000188:drug therapy / Q000191:economics; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000191:economics*; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000191:economics; D054328:Proton Pump Inhibitors; D017494:Proton Pumps / Q000191:economics / Q000627:therapeutic use
chemical_list: D000897:Anti-Ulcer Agents; D054328:Proton Pump Inhibitors; D017494:Proton Pumps; D000658:Amoxicillin; D017291:Clarithromycin